Page 10 - Dtx Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Print DTx Pharma, a 15-employee San Diego biotechnology company pursuing a platform for creating RNA-based therapies to treat genetic drivers of rare diseases, said Monday that it has raised $100 million in Series B round of financing. The early stage company, which previously raised $10.6 million in a Series A round in January 2020, is pursuing potential treatments in ophthalmology and for neuromuscular diseases initially. According to DTx Pharma’s website, its most advanced program in the eye arena targets a disease called retinitis pigmentosa, which is often inherited. It anticipates ini...

The Fifth Annual Retina Fellow Summit This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. 2.00 CME Activity Expiration Date: 12/31/2021 Activity Overview This activity features highlights captured from the Fifth Annual Retina Fellow Summit held in November 2020. The Summit included an expert faculty panel and an audience of retina fellows engaging in discussions on current clinical data, clinical cases, and practice transitions. The overall goal of this program is to provide retina fellows, ophthalmology residents, retina ...